Conversion of intensive therapy with rapid insulin to lispro insulin in type-1 diabetes. A cost-effectiveness assessment;Conversión de la terapia intensiva con insulina rápida a insulina lispro en la diabetes tipo 1. Análisis farmacoeconómico de coste-efectividad

Revista Clinica Espanola

Volumn 201, Issue 8, 2001, Pages 448-454

  Costa Pinel, B ^a,d,e   Belmonte Serrano, M ^c   Paez Vives F ^b   Sabate Obiol A ^d   Estopa Sanchez A ^a   Borras Borras J ^a  

^a Unidad de Diabetes   (Spain)

^b Hospital Comarcal Mora d'Ebre   (Spain)

^c HOSPITAL GENERAL DE CASTELLÓN   (Spain)

^d Centro de Diabetes Salou   (Spain)

^e Consulta de Diabetes Salou ^*  (Spain)

Author keywords

Cost effectiveness; Insulin therapy; Lispro; Pharmacoeconomics; Type 1 diabetes

Indexed keywords

C PEPTIDE; HEMOGLOBIN A1C; INSULIN; INSULIN LISPRO; ISOPHANE INSULIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CROSSOVER PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MALE; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL;

EID: 0343724586     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2565(01)70877-6     Document Type: Article

References (41)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in IDDM. N Eng J Med 1993; 329:977-986.
2. Costa B, Arroyo J, Sabaté A. The economics of pharmacotherapy for diabetes mellitus. PharmacoEconomics 1997; 11:139-158.
3. Home PD. Replacing insulin injections. Diabetic Med 1989; 6:289-290.
4. The Diabetes Control and Complications Trial Research Group. Resource utilization and costs of care in the diabetes control and complications trial. Diabetes Care 1995; 18:1.468-1.478.
5. Braak EW, Woodworth JR, Bianchi R, Cerimele B, Erkelens DW, Thijssen JH, Kurtz D. Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin. Diabetes Care 1996; 19: 1.437-1.440.
6. Barnet AH, Owens DR. Insulin analogues. Lancet 1997; 349:47-51.
7. Bolli GB, Di Marchi RD, Park GD, Pramming S, Koivisto VA. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 1999; 42:1.151-1.167.
8. Gale EA. A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with type 1 diabetes on intensified insulin therapy. The UK Trial Group. Diabet Med 2000; 17:209-214.
9. Jansson PA. Ebelling P, Smith U, et al. Improved glycemic control can be better maintained with insulin lispro than with human regular insulin. Diab Nutr Metab 1998; 11:194-199.
10. Anderson JH, Brunelle RL, Koivisto VA, Pfützner A, Trautmann ME, Vignati L, DiMarchi R. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group. Diabetes 1997; 46:265-270.
11. Ersser RS, Barlow GB, Drew RG. Hjelm M. Automated quantitative, low pressure, cation-exchange chromatography of haemoglobin variants of midget columns. J Autom Chem 1987; 9:92-96.
12. Costa B, Estopá A, Borrás J, Sabaté A. Diabetes y farmacoeconomía. Eficiencia de los sistemas disponibles para la inyección de insulina en Espana. Atención Primaria 1995; 16:391-396.
13. Brownlee M. Negative consequences of glycation. Metabolism 2000; 49 (suppl 1):9-13.
14. E in subjects with type 1 diabetes mellitus. Diabetic Medicine 1999; 16: 384-387.
15. Colombel A, Murat A, Krempf M, Kuchly-Anton B, Charbonnel B. Improvement of blood glucose control in type 1 diabetic patients treated with lispro and multiple NPH injections. Diabet Med 1999; 16:319-324.
16. 1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps. Diabetes Care 1998; 21:977-982.
17. Renner R, Pfützner A, Trautmann M, Harzer O, Sauter K, Landgraf R, German Humalog-CSII Study Group. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Diabetes Care 1999; 22: 784-788.
18. R Mix75/25™ after a standard test meal in patients with type 2 diabetes mellitus. Clin Ther 2000; 22:222-230.
19. Jovanovic L, Ilic S, Pettit DJ, Hugo K, Gutiérrez M, Bowsher RR, Bastyr EJ. Metabolic and immunologic effects of insulin lispro in gestational diabetes. Diabetes Care 1999; 22:1.422-1.427.
20. Raine CH, Krzyston MJ, Amr M, Hydrick L. Improvement in severe insulin resistance with frequent injections of lispro insulin. J Natl Med Assoc 1999; 91:410-413.
21. Holleman F, van den Brand JJ. Hoven RA, van der Linden JM, Van der Tweel I, Hoekstra JB, Erkelens DW. Comparison of LysB28, ProB29-human insulin analog and regular human insulin in the correction of incidental hyperglycemia. Diabetes Care 1996; 19:1426-1429.
22. Del Sindaco P, Ciofetta M, Lalli C, et al. Use of the short-acting insulin analogue lispro in intensive treatment of type 1 diabetes mellitus: importance of appropiate replacement of basal insulin and time-interval injection-meal. Diabet Med 1998; 15:592-600.
23. Rassam AG. Zeise TM, Burge MR, Schade DS. Optimal administration of lispro insulin in hyperglycemic type 1 diabetes. Diabetes Care 1999; 22:133-136.
24. Ahmed AB, Mallias J, Home PD. Optimization of evening insulin dose in patients using the short-acting insulin analog lispro. Diabetes Care 1998; 21:1.162-1.166.
25. Ahmed AB. Home PD. Optimal provision of daytime NPH insulin in patients using the insulin analog lispro. Diabetes Care 1998; 21:1.707-1.713.
26. Costa B, Belmonte M. Cost implications of wastage of drugs. Focus on insulin. Pharmacoeconomics 1994; 6:1-4.
27. Pampanelli S, Torlone E, Lalli C, et al. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function. Diabetes Care 1995; 18:1.452-1.459.
28. Lalli C, Ciofetta M, Del Sindaco P, et al. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Diabetes Care 1999; 22:468-477.
29. Joseph SE, Korzon-Burakowska A, Woodworth JR, Evans M, Hopkins I. Janes JM, Amiel SA. The action profile of lispro is not blunted by mixing in the syring with NPH insulin. Diabetes Care 1998; 21:2.098-2.102.
30. Reichard P. A risk-benefit assessment of conventional versus intensive insulin therapy. Drug Saf 1994; 10:196-202.
31. Heinemann L. Hypoglycemia and insulin analogues: is there a reduction in the incidence? J Diabetes Complications 1999; 13:105-114.
32. Brunelle BL, Llewelyn J. Anderson JH, Gale EA, Koivisto VA. Meta-anaiysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 1998; 21:1.726-1.731.
33. Bolli GB. Prevention and treatment of hypoglycaemia unawareness in type 1 diabetes mellitus. Acta Diabetol 1998; 35:183-193.
34. Sacristán J, Gomis R, Marañes JP, Ricart W, Anderson JH, Reviriego J. Cost-effectiveness of insulin lispro versus regular insulin in patients with type 1 diabetes based on severe hypoglycemia occurrence. Diabetes 2000; 49 (suppl 1):A223.
35. The Diabetes Control and Complications Trial Research Group. The absence of a glycemia threshold for the development of a long-term complications: the perspective of the diabetes control and complications dial. Diabetes 1996; 45:1.289-1.298.
36. The Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. JAMA 1996; 276:1.409-1.415.
37. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brun JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the Diabetes Control and Complications Trial. JAMA 1998; 280:140-146.
38. Egger M, Davey Smith G, Stettler C, Diem P. Risk of adverse effects of intensified treatment in insulin-dependent diabetes mellitus: a meta-analysis. Diabet Med 1997; 14:919-928.
39. Herman WH, Eastman RC. The effects of treatment on the direct costs of diabetes. Diabetes Care 1998; 21 (suppl 3):C19-C24.
40. Bolli GB. How to ameliorate the problem of hypoglycemia in intensive as vs as non intensive treatment of type 1 diabetes. Diabetes Care 1999 22 (suppl 2); B43-B52.
41. Davey P, Grainger D,MacMillan J, Rajan N, Aristides M, Dobson M. Economic evaluation of insulin lispro versus neutral (regular) insulin therapy using a willingness-to-pay approach. Pharmacoeconomics 1998; 13:347-358.